The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome. Editorial on Serebruany. "Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified" (Thromb Haemost 2011; 105.5).
Publication
, Journal Article
Wallentin, L; Becker, RC; James, SK; Harrington, RA
Published in: Thromb Haemost
May 2011
Duke Scholars
Published In
Thromb Haemost
DOI
EISSN
2567-689X
Publication Date
May 2011
Volume
105
Issue
5
Start / End Page
760 / 762
Location
Germany
Related Subject Headings
- United States
- Treatment Outcome
- Ticlopidine
- Ticagrelor
- Survival Rate
- Research Design
- Humans
- Genetic Predisposition to Disease
- Europe
- Clopidogrel
Citation
APA
Chicago
ICMJE
MLA
NLM
Wallentin, L., Becker, R. C., James, S. K., & Harrington, R. A. (2011). The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome. Editorial on Serebruany. "Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified" (Thromb Haemost 2011; 105.5). Thromb Haemost, 105(5), 760–762. https://doi.org/10.1160/TH11-03-0162
Wallentin, L., R. C. Becker, S. K. James, and R. A. Harrington. “The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome. Editorial on Serebruany. "Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified" (Thromb Haemost 2011; 105.5).” Thromb Haemost 105, no. 5 (May 2011): 760–62. https://doi.org/10.1160/TH11-03-0162.
Wallentin L, Becker RC, James SK, Harrington RA. The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome. Editorial on Serebruany. "Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified" (Thromb Haemost 2011; 105.5). Thromb Haemost. 2011 May;105(5):760–2.
Wallentin, L., et al. “The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome. Editorial on Serebruany. "Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified" (Thromb Haemost 2011; 105.5).” Thromb Haemost, vol. 105, no. 5, May 2011, pp. 760–62. Pubmed, doi:10.1160/TH11-03-0162.
Wallentin L, Becker RC, James SK, Harrington RA. The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome. Editorial on Serebruany. "Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified" (Thromb Haemost 2011; 105.5). Thromb Haemost. 2011 May;105(5):760–762.
Published In
Thromb Haemost
DOI
EISSN
2567-689X
Publication Date
May 2011
Volume
105
Issue
5
Start / End Page
760 / 762
Location
Germany
Related Subject Headings
- United States
- Treatment Outcome
- Ticlopidine
- Ticagrelor
- Survival Rate
- Research Design
- Humans
- Genetic Predisposition to Disease
- Europe
- Clopidogrel